OSCR Oscar Health, Inc. Insider Trading

CFO Blackley Richard Scott sold 110,000 shares of OSCR at $25.03 on 2026-05-18 per 10b5-1 plan; stock up 70.6% in 90 days

Blackley Richard Scott, CFO of Oscar Health, sold 110,000 shares (110.0K shares) for $2,753,300.00 ($2.8M) on 2026-05-18 under a pre-arranged 10b5-1 trading plan adopted on 2026-02-12, leaving him with 1,106,660 shares (1.11M shares) post-transaction. The sale occurred when OSCR was trading at $25.03, near its 52-week high of $25.58, and follows a strong 70.6% 90-day run and 42.5% 30-day surge. Because this transaction is scheduled under a 10b5-1 plan rather than discretionary, the timing reflects pre-set mechanics rather than an active trading decision. His prior open-market sells (5 trades across all tickers) averaged +7.7% 30-day returns and -1.7% 90-day returns, suggesting a historical pattern where post-sale price action has drifted lower on the 90-day horizon; at the specific ticker OSCR, his 5 prior sales showed mixed outcomes ranging from -14.3% to +18.0% over 30 days. The company fundamentals show $4,647,194,000.00 ($4.6B) revenue (latest quarter) with 27.5% annual growth, but net income of $678,996,000.00 ($679.0M) came in a period when full-year profitability was negative.

CFO Blackley Richard Scott sold 100,000 OSCR shares at $23.16 blended average on 2026-05-14 via scheduled 10b5-1 plan, retaining 1.22M shares.

Chief Financial Officer Blackley Richard Scott executed 2 separate sales totaling 100,000 shares for $2,316,031.29 on 2026-05-14 under a 10b5-1 trading plan adopted on 2026-02-12—a scheduled, non-discretionary transaction. The sale reduced his holdings by 7.6% to 1.22M shares. Because this trade is governed by a pre-arranged plan, no timing-based inference about conviction or market outlook is warranted. His prior sales at Oscar Health have shown mixed retrospective outcomes: 30-day returns ranging from −14.3% to +18.0%, and 90-day returns from −10.9% to +3.0%. The company reported $4.6B in quarterly revenue and $679.0M in net income for the latest quarter, though it remains unprofitable on a full-year basis despite +27.5% annual revenue growth. Current price of $25.30 lies 4.2% above the 52-week high of $24.28, representing a 60.2% gain over the prior 30 days.